ArticleNature communications2020
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 81 papers.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 129 citations in OpenAlex.
- Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.Nature cancer · 2025Trial
- The peripheral immune landscape of human breast cancer.Oncoimmunology · 2026Review
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression.Oncogene · 2026Article
- Autophagy modulation in cancer.Nature reviews. Drug discovery · 2026Review
- Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women.Nature aging · 2026Article
- Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer.Nature communications · 2026Article
- The advent of precision nutrigeroscience in cancer: from clinic towards molecular biology.Journal of advanced research · 2026Review
- NKG2A inhibition promotes NK cell-CD8Nature communications · 2026Article
- Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade.Molecular cancer · 2026Review
- Isoflavones impair anti-PD1 efficacy in breast cancer, regardless of dietary fiber or fecal short-chain fatty acid levels.Frontiers in immunology · 2026Article
- B vitamins intake and cancer risk: a structured narrative review of evidence on riboflavin, pyridoxine, cobalamin and folate.Pathology oncology research : POR · 2026Review
- Paradoxical control of multifocal mammary oncogenesis by radiation therapy.Oncoimmunology · 2025Article
- An immunological mechanism of resistance to CDK4/6 inhibitors in HROncoimmunology · 2025Article
- Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.Oncoimmunology · 2025Article
- ACBP/DBI neutralization for the prevention and treatment of malignant and non-malignant liver diseases.Cell death & disease · 2025Review
- Stromal senescence contributes to age-related increases in cancer.Nature reviews. Cancer · 2025Review
- TIM-3 and γδ T cells: new players in breast cancer dissemination.The EMBO journal · 2025Article
- Metabolites as agents and targets for cancer immunotherapy.Nature reviews. Drug discovery · 2025Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
30 authors at 9 institutions in 7 countries.
Aitziber BuquéDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-7698-8778
Norma BloyDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Maria Perez-LanzónEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Kristina IribarrenEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Juliette HumeauEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Jonathan G PolEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Sarah LevesqueEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Laura MondragonEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Takahiro YamazakiDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-7420-4394
Ai SatoDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-5408-2596
Fernando ArandaEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.ORCID http://orcid.org/0000-0002-9364-474X
Sylvère DurandEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Alexandre BoissonnasSorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses CIMI, Paris, France.
Jitka FucikovaSotio, Prague, Czech Republic.
Laura SenovillaEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
David EnotEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Michal HenslerSotio, Prague, Czech Republic.
Margerie KremerEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Gautier StollEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.ORCID http://orcid.org/0000-0002-0862-4139
Yang HuCaryl and Israel Englander Institute for Precision Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-6348-874X
Chiara MassaInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Silvia C FormentiDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-8227-8924
Barbara SeligerInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine, New York, NY, USA.
Radek SpisekSotio, Prague, Czech Republic.
Fabrice AndréGustave Roussy Cancer Center, Villejuif, France.ORCID http://orcid.org/0000-0001-5795-8357
Laurence ZitvogelFaculté de Médecine, Université de Paris Sud, Paris-Saclay, Le Kremlin-Bicêtre, Paris, France.
Suzette DelalogeDepartment of Cancer Medicine, Gustave Roussy Cancer Center, Villejuif, France.ORCID http://orcid.org/0000-0003-2106-9165
Guido KroemerEquipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. kroemer@orange.fr.ORCID http://orcid.org/0000-0002-9334-4405
Lorenzo GalluzziDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. deadoc80@gmail.com.ORCID http://orcid.org/0000-0003-2257-8500
Inserm · FRCornell University · USCharles University · CZInstitut Gustave Roussy · FRLander Institute · ILMartin Luther University Halle-Wittenberg · DECentre National de la Recherche Scientifique · FRKarolinska University Hospital · SESotio (Czechia) · CZ
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hormone receptor (HR)
Indexed as
9,10-Dimethyl-1,2-benzanthraceneAnimalsBreast NeoplasmsCarcinogenesisDisease ProgressionErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunotherapyInterferon Type IMammary Neoplasms, ExperimentalMedroxyprogesterone AcetateMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutNiacinamide9,10-Dimethyl-1,2-benzanthraceneErb-b2 Receptor Tyrosine KinasesInterferon Type IMedroxyprogesterone AcetateNiacinamide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.